by Leslie Gladstone Restaino The explosion of Life sciences innovation and the globalization of the marketplace have heightened the importance of intel1ectual property (IP) in […]
Understanding Your Patent Portfolio, Reducing Risk Through Due Diligence Read More »
by Leslie Gladstone Restaino The explosion of Life sciences innovation and the globalization of the marketplace have heightened the importance of intel1ectual property (IP) in
Understanding Your Patent Portfolio, Reducing Risk Through Due Diligence Read More »
FOR IMMEDIATE RELEASE Contact: Monica Malave Director, Marketing & Communications mmalave@axendia.com Yardley, PA, October 24, 2006 — Axendia, a trusted advisor to
Axendia Joins Forces with Microsoft to Strengthen BioIT Alliance Read More »
Source: Microsoft Corp. Yesterday, at Microsoft’s biotechnology Executive Forum, Microsoft announced the initiation of the BioIT Alliance’s second proof of concept, called the Biomarkers Project,
Can Microsoft Accelerate the Pace of Drug Discovery and Development? Read More »
On February 26, 2004, the FDA published its final rule on “Bar Code Label Requirements for Human Drug Products and Biological Products”. According to the
A Bar-Code In The Hand Is Worth Two RFID Tags In The Bush Read More »
By Daniel R. Matlis In my “Final Word” column, published in Pharmaceutical Formulation and Quality, I discussed the need to deepen our industry’s gene pool.
It’s Time to Deepen the Gene Pool Read More »
By Daniel R. Matlis According to a recent study by the Milken Institute the life sciences industry is an emerging powerhouse for U.S. global
Life Sciences Industry is an Emerging Powerhouse in Pennsylvania Read More »
By Daniel R. Matlis Yesterday, on the heels of the release of a critical Institute of Medicine Report, the FDA issued a Final Guidance
FDA Issues Final cGMP Guidance Read More »
By Daniel R. Matlis According to a report issued by the Institute of Medicine (IOM), the FDA suffers from a lack of clear regulatory authority,
FDA Drug Safety System Needs Fixing, IOM Report Says Read More »
By Leslie Gladstone Restaino, Esq. ImClone Systems, Inc. is reeling from a court decision Monday invalidating ownership of a significant patent for the company’s cancer
ImClone Loses Patent Decision for Cancer Drug Erbitux Read More »
By Daniel R. Matlis Recently, I wrote an article calling for consistent federal regulatory requirements for the practice of compounding. Last month, the US District
The U.S. Food and Drug Administration (FDA) yesterday approved the AbioCor®, the world’s first completely self-contained, implantable Replacement Heart. This approval provides patients suffering from
FDA Approves First Implantable Replacement Heart Read More »
